Financing included participation by healthcare-dedicated investors alongside existing shareholdersTORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct offering of 5,142,870 common shares at a purchase price of $7.00 per share, for gross proceeds of approximately $36 million before fees and expenses. The registered direct offering was structured as a straightforward equi ...

Core Insights - Profound Medical Corp. is a commercial-stage medical device company focused on developing AI-powered, incision-free therapies for tissue ablation [3][4] Company Overview - Profound Medical Corp. is engaged in the commercialization of TULSA-PRO®, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for prostate disease treatment [4] - The TULSA Procedure™ is designed to treat various prostate conditions, including low-, intermediate-, and high-risk prostate cancer, benign prostatic hyperplasia (BPH), and salvage therapy for radio-recurrent localized prostate cancer [4] - The TULSA Procedure is characterized as a "one-and-done" treatment, performed in a single session without incisions or radiation, with a typical duration of a few hours [4] - The procedure utilizes precise sound absorption technology to heat targeted prostate tissue to 55-57°C, preserving urinary continence and sexual function [4] - TULSA-PRO has received CE marking, Health Canada approval, and 510(k) clearance from the U.S. FDA [4] Additional Products - Profound is also commercializing Sonalleve®, a therapeutic platform approved for treating uterine fibroids and palliative pain from bone metastases [5] - Sonalleve has received CE marking and approval from the China National Medical Products Administration for non-invasive treatment of uterine fibroids, as well as FDA approval under a Humanitarian Device Exemption for osteoid osteoma treatment [5] - The company is exploring further treatment applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy [5] Upcoming Events - Management will present a business update at the Stifel 2025 Healthcare Conference on November 11, 2025, at 1:20 p.m. Eastern Time [1][2]

Core Viewpoint - Profound Medical Corp. anticipates significant revenue growth for Q3 2025, with preliminary estimates indicating revenues between $5.2 million and $5.3 million, representing an increase of 84% to 87% compared to the same period last year [2][3] Financial Performance - For the quarter ended September 30, 2025, Profound expects total revenues in the range of $5.2 million to $5.3 million, up from $2.8 million in Q3 2024 [2] - The gross margin for Q3 2025 is projected to be approximately 72%, an increase from 64% in the prior year [2] Business Developments - The installed base of the TULSA-PRO system has grown to 67 units, up from 60, with expectations to reach at least 75 by the end of the year due to a strong capital sales pipeline [3] - The TULSA Procedure is positioned as a potential mainstream treatment for various prostate conditions, emphasizing its incision-free and radiation-free nature [6] Upcoming Events - The company will release its full Q3 2025 financial results on November 13, 2025, followed by a conference call at 4:30 p.m. ET to discuss the results and business developments [4]

Core Insights - Profound Medical Corp. reported its second quarter financial results for 2025, highlighting growth in TULSA-PRO system utilization and a strong sales pipeline, despite experiencing short-term delays in capital sales [1][3]. Business Highlights - Utilization of TULSA-PRO systems increased, with "same store" procedure volumes rising by 10% sequentially from Q1-2025 [2]. - The sales pipeline for TULSA-PRO has expanded to 80 new systems in various stages of the sales process [2]. - Patient demographics treated with TULSA-PRO in Q2-2025 included 79% for prostate cancer, 17% for hybrid conditions, and 3% for salvage therapy [2]. - The company hosted an investor event at the AUA 2025, showcasing positive initial data from the CAPTAIN trial, which indicated TULSA's advantages over robotic radical prostatectomy [2]. - Leonard Wheeler was appointed as Global Ambassador for TULSA-PRO to enhance awareness and advocacy [2]. - The TULSA-AI Volume Reduction Module was successfully launched for BPH treatment, with a full launch expected in Q4-2025 [3]. Financial Performance - Revenue for Q2-2025 was approximately $2.2 million, with $1.6 million from recurring non-capital revenue and $650,000 from capital equipment sales [4]. - Gross margin improved to 73% in Q2-2025, up from 64% in the prior year, attributed to higher manufacturing efficiency [5]. - Total operating expenses rose to approximately $15.4 million, compared to $9.3 million in the previous year, driven by increased headcount and trial enrollment [6]. - The net loss for Q2-2025 was approximately $15.7 million, or $0.52 per share, compared to a loss of $6.9 million, or $0.28 per share, in Q2-2024 [7]. Liquidity and Share Capital - As of June 30, 2025, the company had cash reserves of approximately $35.2 million [8]. - The total number of common shares outstanding was 30,053,142 as of August 14, 2025 [8].